Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo  >  Shionogi & Co Ltd    4507   JP3347200002


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

GSK wins U.S. nod for two-drug HIV combination

share with twitter share with LinkedIn share with facebook
share via e-mail
04/08/2019 | 04:47pm EDT
The GSK logo on the facade of GSK Asia House is seen through vertical louvres in Singapore

(Reuters) - GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

The U.S. Food and Drug Administration cleared the combination of dolutegravir and lamivudine, to be branded as Dovato, for use in newly diagnosed adults.

GSK showed in drug trials last year that the once-a-day Dovato pill was as good as a standard three-drug cocktail in suppressing the virus that causes AIDS and also in terms of tolerability.

GSK's HIV drugs division ViiV, in which Pfizer Inc and Shionogi & Co Ltd have small stakes, will use the lower drug burden as its main selling point to patients and physicians, while hoping that longer-term studies will yield hard evidence of fewer side effects over time.

As HIV positive patients grow older thanks to highly effective treatment, the focus shifts to long-term side effects as nearly half of all HIV patients in the profitable markets of North America and Europe are now over 50.

"We are trying to establish a new normal for people with HIV. We absolutely believe that people living with HIV should not take more medicines than they need," said Deborah Waterhouse, who heads the British drugmaker's HIV unit.

ViiV accounted for about 39 percent of GSK's group operating profit last year, according to UBS analysts. With a 23 percent share in the $26 billion-a-year HIV market, it is seeking to catch up with Gilead's 53 percent.

Gilead will keep up the pressure with new anti-retroviral drug Biktarvy, a combination of three HIV medicines in a daily tablet, which was approved early last year. Market researcher Evaluate pharma expects sales from the product to reach $6.1 billion in 2024.

Hopes for growth - despite harsh competition from Gilead - rest on Dovato as well as on another two-drug combination that will be given as a monthly injection but regulatory approval of the latter is not expected before next year.

The company's growth prospects are clouded by the recent U.S. launch of cheap generic copies of blockbuster asthma treatment Advair, generated 2.4 billion pounds in revenues for GSK last year.

GSK already has two-drug regimen Juluca on the market, but only for the smaller market of HIV patients that have received prior treatment. Dovato is the first such product for new cases.

(Additional reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta and Marguerita Choy)

By Ludwig Burger

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 1.00% 66.52 Delayed Quote.6.35%
GLAXOSMITHKLINE 0.46% 1551.2 Delayed Quote.3.58%
PFIZER 0.19% 41.67 Delayed Quote.-4.72%
SHIONOGI & CO LTD 0.11% 6422 End-of-day quote.4.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIONOGI & CO LTD
04/26GlaxoSmithKline Subsidiary Gets Positive Opinion for HIV Drug
04/22SHIONOGI : Notice of Revisions to Dividend Forecasts
04/15SHIONOGI : Acquisition of Marketing Approval for VYVANSE Capsule 20mg/30mg for T..
04/12BIODELIVERY SCIENCES INTERNATIONAL : Shionogi Announces Licensing of Symproic to..
04/12SHIONOGI : Acquisition of Marketing Approval for VYVANSE® Capsule 20mg/30mg for ..
04/11BIODELIVERY SCIENCES INTERNATIONAL : Acquires U.S. Commercial Rights to Symproic
04/08GSK wins U.S. nod for two-drug HIV combination
04/05SHIONOGI : to Present New Data at European Congress of Clinical Microbiology and..
04/05SHIONOGI : to Present Clinical Data on Lusutrombopag at the International Liver ..
04/04SHIONOGI : to Present New Data at European Congress of Clinical Microbiology and..
More news
Financials (JPY)
Sales 2020 365 B
EBIT 2020 -
Net income 2020 128 B
Finance 2020 405 B
Yield 2020 1,53%
P/E ratio 2020 15,55
P/E ratio 2021 14,52
EV / Sales 2020 4,46x
EV / Sales 2021 4,05x
Capitalization 2 032 B
Duration : Period :
Shionogi & Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIONOGI & CO LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 7 623  JPY
Spread / Average Target 19%
EPS Revisions
Isao Teshirogi President & Representative Director
Motozo Shiono Chairman
Kohji Hanasaki Manager-Accounting & Finance
Akio Nomura Independent Director
Teppei Mogi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIONOGI & CO LTD4.00%18 393
JOHNSON & JOHNSON7.26%367 513
PFIZER-4.72%231 237
ROCHE HOLDING LTD.9.70%226 519
NOVARTIS12.54%207 417